Brian  Lenz net worth and biography

Brian Lenz Biography and Net Worth

Mr. Lenz joined ADMA as Vice President, Chief Financial Officer in May 2012 and was instrumental in preparing the Company to go public and begin trading on the NASDAQ in October 2013. In June 2018, Mr. Lenz was promoted to Executive Vice President and Chief Financial Officer.  Mr. Lenz co-led the Biotest Therapy Business Unit (“BTBU”) acquisition team.  In this role, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction.

Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s financial reporting and SOX compliance activities amongst other operational duties.

Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.

Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.

Mr. Lenz is the finance committee co-chairperson for BioNJ.  He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.

Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include:  Best Growth Manager, Financier of the Year, Public Company and Capital Success.

What is Brian Lenz's net worth?

The estimated net worth of Brian Lenz is at least $3.05 million as of August 15th, 2023. Mr. Lenz owns 782,013 shares of ADMA Biologics stock worth more than $3,049,851 as of December 6th. This net worth evaluation does not reflect any other investments that Mr. Lenz may own. Additionally, Mr. Lenz receives an annual salary of $1,080,000.00 as CFO at ADMA Biologics. Learn More about Brian Lenz's net worth.

How old is Brian Lenz?

Mr. Lenz is currently 51 years old. There are 2 older executives and no younger executives at ADMA Biologics. The oldest executive at ADMA Biologics is Dr. Jerrold B. Grossman D.P.S., Ph.D., Co-Founder & Vice Chairman of the Board, who is 75 years old. Learn More on Brian Lenz's age.

What is Brian Lenz's salary?

As the CFO of ADMA Biologics, Inc., Mr. Lenz earns $1,080,000.00 per year. The highest earning executive at ADMA Biologics is Mr. Adam S. Grossman, Co-Founder, President, CEO & Director, who commands a salary of $1,520,000.00 per year. Learn More on Brian Lenz's salary.

How do I contact Brian Lenz?

The corporate mailing address for Mr. Lenz and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]. Learn More on Brian Lenz's contact information.

Has Brian Lenz been buying or selling shares of ADMA Biologics?

Brian Lenz has not been actively trading shares of ADMA Biologics within the last three months. Most recently, Brian Lenz sold 211,578 shares of the business's stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $4.60, for a transaction totalling $973,258.80. Following the completion of the sale, the chief financial officer now directly owns 782,013 shares of the company's stock, valued at $3,597,259.80. Learn More on Brian Lenz's trading history.

Who are ADMA Biologics' active insiders?

ADMA Biologics' insider roster includes Adam Grossman (CEO), Young Kwon (Director), and Brian Lenz (CFO). Learn More on ADMA Biologics' active insiders.

Are insiders buying or selling shares of ADMA Biologics?

During the last year, ADMA Biologics insiders bought shares 4 times. They purchased a total of 176,976 shares worth more than $642,651.36. During the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 2,405,351 shares worth more than $9,875,174.54. The most recent insider tranaction occured on August, 30th when Director Jerrold B Grossman bought 130,000 shares worth more than $482,300.00. Insiders at ADMA Biologics own 5.9% of the company. Learn More about insider trades at ADMA Biologics.

Information on this page was last updated on 8/30/2023.

Brian Lenz Insider Trading History at ADMA Biologics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2023Sell211,578$4.60$973,258.80782,013View SEC Filing Icon  
12/9/2022Buy6,993$2.86$19,999.981,034,825View SEC Filing Icon  
10/25/2021Buy30,000$1.00$30,000.00View SEC Filing Icon  
8/11/2020Buy4,000$2.97$11,880.00View SEC Filing Icon  
2/11/2020Buy7,142$3.50$24,997.0032,142View SEC Filing Icon  
5/17/2019Buy5,000$4.00$20,000.0025,000View SEC Filing Icon  
6/8/2018Buy5,000$4.78$23,900.0020,000View SEC Filing Icon  
11/9/2017Buy6,500$2.15$13,975.0015,000View SEC Filing Icon  
5/3/2016Buy2,500$6.50$16,250.008,500View SEC Filing Icon  
12/2/2015Buy1,000$9.15$9,150.006,000View SEC Filing Icon  
5/14/2014Buy1,000$7.50$7,500.00View SEC Filing Icon  
See Full Table

Brian Lenz Buying and Selling Activity at ADMA Biologics

This chart shows Brian Lenz's buying and selling at ADMA Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ADMA Biologics Company Overview

ADMA Biologics logo
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Read More

Today's Range

Now: $3.90
Low: $3.85
High: $3.93

50 Day Range

MA: $3.56
Low: $3.08
High: $4.03

2 Week Range

Now: $3.90
Low: $2.94
High: $4.65


358,781 shs

Average Volume

2,189,083 shs

Market Capitalization

$881.28 million

P/E Ratio


Dividend Yield